PR 104

Drug Profile

PR 104

Alternative Names: PR-104; SN-29244

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proacta Therapeutics
  • Developer Proacta; Proacta Therapeutics
  • Class Antineoplastics; Benzamides; Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Solid tumours
  • Discontinued Hepatocellular carcinoma; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 22 Sep 2015 No recent reports on development identified - Phase-I for Solid tumours in New Zealand (IV)
  • 22 Sep 2015 No recent reports on development identified - Phase-I/II for Acute myeloid leukaemia in USA (IV)
  • 15 Nov 2011 Adverse events data from a phase I trial in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top